A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma ...
Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...
Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...
The agreement will give Kuro enough capital to support the development and launch of its menin inhibitor ziftomenib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback